Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events

Nature Biotechnology

Volumn 26, Issue 6, 2008, Pages 669-675

  Guerrini, Marco ^a   Beccati, Daniela ^b   Shriver, Zachary ^b,c   Naggi, Annamaria ^a   Viswanathan, Karthik ^c   Bisio, Antonella ^a   Capila, Ishan ^b   Lansing, Jonathan C ^b   Guglieri, Sara ^a   Fraser, Blair ^d   Al Hakim, Ali ^d   Gunay, Nur Sibel ^b   Zhang, Zhenqing ^e   Robinson, Luke ^c   Buhse, Lucinda ^d   Nasr, Moheb ^d   Woodcock, Janet ^d   Langer, Robert ^c   Venkataraman, Ganesh ^b,c   Linhardt, Robert J ^e   Casu, Benito ^a   Torri, Giangiacomo ^a   Sasisekharan, Ram ^c   more..

^a Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^b Momenta Pharmaceuticals Inc   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MICROFLUIDICS; PHOTOACOUSTIC EFFECT; STRUCTURAL ANALYSIS; SULFATE MINERALS; SULFUR COMPOUNDS;

ANALYTICAL TECHNIQUES; CHONDROITIN SULFATE (CHSA); GALACTOSAMINE; GLUCURONIC ACIDS; HEPARIN (HEP); HIGH RESOLUTIONS; SCREENING METHODS; SCREENING TESTS; SIDE EFFECTS;

POLYSACCHARIDES;

CHONDROITIN 4 SULFATE; CHONDROITIN SULFATE; DERMATAN SULFATE; HEPARIN;

ANTICOAGULANT THERAPY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; DRUG CONTAMINATION; DRUG HYPERSENSITIVITY; HUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCREENING TEST; STRUCTURE ANALYSIS; SULFATION;

CHONDROITIN SULFATES; DRUG CONTAMINATION; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HEPARIN; HUMANS;

EID: 45149118311     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1407     Document Type: Article

References (29)

1. Capila, I. & Linhardt, R.J. Heparin-protein interactions. Angew. Chem. Int. Edn. Engl. 41, 391-412 (2002).
2. Lepor, N.E. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. Rev. Cardiovasc. Med. 8 (suppl. 3), S9-S17 (2007).
3. Fischer, K.G. Essentials of anticoagulation in hemodialysis. Hemodial. Int. 11, 178-189 (2007).
4. Contaminant detected in heparin material of specified origin in the USA and in Germany; serious adverse events reported; recall measures initiated. World Health Organization Alert No. 118 (7 March 2008). 〈http://www.who. int/medicines/publications/drugalerts/Alert_118_Heparin.pdf〉
5. Notice of Recall from Rotexmedica to Bfarm (German Regulatory Authorities). Rotexmedica/Bfarm Notice (7 March 2008). 〈http://www.akdae. de/20/40/Archiv/2008/20080310.pdf〈
6. Acute allergic-type reactions among patients undergoing hemodialysis - multiple states, 2007-2008. Morbid. Mortal. Wkly Rept. 57 (1 February 2008).
7. 2008 Heparin Recall Information. Baxter Investigation Updates (5,14,19 March 2008). 〈http://www.baxter.com/products/biopharmaceuticals/heparin. html〉
8. Baxter provides update on investigation. Baxter Investigation Update (14 March 2008). 〈http://www.baxter.com/products/biopharmaceuticals/downloads/ heparin_03-14-08.pdf〉
9. Communication. Information on heparin sodium injection. US Food and Drug Administration. 〈http://www.fda.gov/cder/drug/infopage/heparin/default. htm〉
10. Holme, K.R. & Perlin, A.S. Nuclear magnetic resonance spectra of heparin in admixture with dermatan sulfate and other glycosaminoglycans. 2-D spectra of the chondroitin sulfates. Carbohydr. Res. 186, 301-312 (1989).
11. 13C nuclear magnetic resonance spectroscopy for characterization of heparin preparations. Semin. Thromb. Hemost. 27, 473-482 (2001).
12. Myette, J.R. et al. Molecular cloning of the heparin/heparan sulfate delta 4,5 unsaturated glycuronidase from Flavobacterium heparinum, its recombinant expression in Escherichia coli, and biochemical determination of its unique substrate specificity. Biochemistry 41, 7424-7434 (2002).
13. Myette, J.R. et al. The heparin/heparan sulfate 2-O-sulfatase from Flavobacterium heparinum. Molecular cloning, recombinant expression, and biochemical characterization. J. Biol. Chem. 278, 12157-12166 (2003).
14. Kuberan, B. et al. Analysis of heparan sulfate oligosaccharides with ion pair-reverse phase capillary high performance liquid chromatography-microelectrospray ionization time-of-flight mass spectrometry. J. Am. Chem. Soc. 124, 8707-8718 (2002).
15. Maruyama, T., Toida, T., Imanari, T., Yu, G. & Linhardt, R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr. Res. 306, 35-43 (1998).
16. Solvolytic desulfation of glycosaminoglycuronan sulfates with dimethyl sulfoxide containing water or methanol. Nagasawa, K., Inoue, Y. & Kamata, T. Carbohydr. Res. 58, 47-55 (1977).
17. Linhardt, R.J. Analysis of glycosaminoglycans with polysaccharide lyases. in Current Protocols in Molecular Biology (eds. Ausubel, F.A. et al.) 17.13B.1-17B.13.16 (Wiley, New York, 1994).
18. Kinoshita, A. et al. Novel tetrasaccharides isolated from squid cartilage chondroitin sulfate E contain unusual sulfated disaccharide units GlcA(3-O-sulfate)β1-3GalNAc(6-O-sulfate) or GlcA(3-O-sulfate)β1-3GalNAc. J. Biol. Chem. 272, 19656-19665 (1997).
19. Hadding, U. et al. Ability of the T cell-replacing polyanion dextran sulfate to trigger the alternate pathway of complement activation. Eur. J. Immunol. 3, 527-529 (1973).
20. Kang, O.H. et al. Suppressive effect of non-anaphylactogenic anti-IgE antibody on the development of dextran sulfate sodium-induced colitis. Int. J. Mol. Med. 18, 893-899 (2006).
21. Siebeck, M. et al. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J. Appl. Physiol. 77, 2675-2680 (1994).
22. Hojima, Y., Cochrane, C.G., Wiggins, H.C., Austen, K.F. & Steven, R.L. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 63, 1453-1459 (1984).
23. Naggi, A. et al. Sulfamino-galactosaminoglycans, a new class of semi-synthetic polysaccharides. in Biomedical and Biotechnological Advances in Industrial Polysaccharides (eds. Crescenzi, V., Dea, I.C.M. & Paoletti, S.) 101-108 (Gordon & Breach Science, New York, 1989).
24. Siegmenth, W. & Radi, I. Comparison of glycosaminoglycan polysulfate (Arteparon) and physiological saline solution in arthrosis of the large joints. Results of a multicenter double-blind study. Z. Rheumatol. 42, 223-228 (1983).
25. Greinacher, A., Michels, I., Schäfer, M., Kiefel, V. & Mueller-Eckhardt, C. Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. Br. J. Haematol. 81, 252-254 (1992).
26. Weimann, G. et al. Glucosamine sulfate does not crossreact with the antibodies of patients with heparin-induced thrombocytopenia. Eur. J. Haematol. 66, 195-199 (2001).
27. Cicero, O., Barbato, G. & Bazzo, R. Sensitivity enhancement of a two-dimensional experiment for the measurement of heteronuclear long-range coupling constants, by a new scheme of coherence selection by gradients. J. Magn. Reson. 148, 209-213 (2001).
28. Cifonelli, J.C. Reaction of heparitin sulfate with nitrous acid. Carbohydr. Res. 8, 233-242 (1968).
29. 15N chemical shift referencing in biomolecular NMR. J. Biomol. NMR 6, 135-140 (1995).